<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202877</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0374</org_study_id>
    <secondary_id>NCI-2012-01896</secondary_id>
    <nct_id>NCT01202877</nct_id>
  </id_info>
  <brief_title>PKC412 and 5-Azacytidine</brief_title>
  <official_title>A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of PKC412 (also&#xD;
      called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute&#xD;
      leukemia and MDS. The safety and best dose of the combination of the drugs will also be&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      PKC412 is designed to block certain receptors (FLT3-Kinase) on cancer cells that are&#xD;
      responsible for cancer growth. This may cause the cancer cells to die.&#xD;
&#xD;
      5-azacytidine is designed to cause changes to certain genes that are thought to participate&#xD;
      in causing leukemia. These changes are thought to silence these genes so they cannot&#xD;
      contribute any longer to sustain the growth of leukemia and MDS.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a part of&#xD;
      the study based on when you join.&#xD;
&#xD;
        -  If you are one of the first 6 participants, you will receive a pre-planned dose of the&#xD;
           study drugs. If 2 participants experience severe side effects, the rest of this group&#xD;
           will receive a lower dose.&#xD;
&#xD;
        -  If you are not one of the first 6 participants, and fewer than 2 patients had severe&#xD;
           side effects in the first group, you will receive the drugs at a higher dose than the&#xD;
           first 6 participants.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will receive 5-azacytidine by vein over about 30 minutes or through a needle under your&#xD;
      skin on Days 1-7 of each 28-day study cycle. Your doctor will decide if you will get the drug&#xD;
      by vein or under the skin. You will be required to return to MD Anderson for the first 7 days&#xD;
      of every cycle to receive 5-azacytidine.&#xD;
&#xD;
      On Days 8-21 of cycle 1, you will take PKC412 capsules by mouth 2 times a day. Starting with&#xD;
      Cycle 2, you will take PKC412 capsules by mouth every day. The research staff will tell you&#xD;
      how to take the study drug and you will also be given instructions.&#xD;
&#xD;
      If you have severe side effects from the study drug, the study doctor may decide to stop drug&#xD;
      dosing until your side effects improve.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At every visit, you will be asked about any side effects you have experienced and to list any&#xD;
      drugs you may be taking.&#xD;
&#xD;
        -  At the start of Cycles 1-2 (+/- 4 days) and then every 2-3 cycles, you will have a&#xD;
           complete physical exam.&#xD;
&#xD;
        -  Every week during Cycles 1-3 (+/- 4 days) and then every 2-4 weeks, blood (about 1&#xD;
           tablespoon) will be drawn for routine tests and to test your kidney and liver function.&#xD;
&#xD;
        -  On Day 28 of Cycle 1 (+/- 4 days) and then every 1-3 cycles, you will have a bone marrow&#xD;
           aspirate to check the status of the disease.&#xD;
&#xD;
        -  On Day 8 (+/- 1 day) of each cycle for the first cycle before initiation of Midostaurin,&#xD;
           then before the start of Midostaurin on Cycle 2, then on Day 1 every 2-3 Cycles, you&#xD;
           will have an ECG.&#xD;
&#xD;
        -  On Days 8, 15, and 21 of Cycle 1 and Day 1 of Cycle 2, blood (about 1 teaspoon) will be&#xD;
           drawn for Pharmacokinetic (PK) testing before you take the study drug.&#xD;
&#xD;
      If you stay on study for longer than 6 months, your doctor will decide what tests and&#xD;
      procedures you will have and when they will be performed. At least every 6-12 months you will&#xD;
      have a bone marrow aspirate.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take the study drug if the disease gets worse or&#xD;
      intolerable side effects occur.&#xD;
&#xD;
      This is an investigational study. PKC412 is not FDA approved or commercially available. It is&#xD;
      currently being used for research purposes only. 5-azacytidine is FDA approved and&#xD;
      commercially available for the treatment of patients with MDS. The combination of these drugs&#xD;
      to treat refractory or relapsed acute leukemia and MDS is investigational.&#xD;
&#xD;
      Up to 54 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response (OR) Within 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>Overall response defined as number of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation. complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacytidine</intervention_name>
    <description>Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.</description>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>5-aza</other_name>
    <other_name>Vidaza</other_name>
    <other_name>5-AZC</other_name>
    <other_name>AZA-CR</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>NSC-102816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PKC412</intervention_name>
    <description>Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
    <arm_group_label>5-azacytidine + PKC412</arm_group_label>
    <other_name>Midostaurin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with MDS, chronic myelomonocytic leukemia (CMML), AML or biphenotypic or&#xD;
             bilineage leukemia who have failed prior therapy. Patients with MDS or CMML should&#xD;
             have failed prior therapy with a hypomethylating agent and/or with lenalidomide.&#xD;
             Patients with AML should have failed any prior induction therapy or have relapsed&#xD;
             after prior therapy, or be previously untreated and unable or unwilling to receive&#xD;
             conventional chemotherapy (e.g., patients age &gt;/=65 years). Patients with MDS or CMML&#xD;
             who received therapy with a hypomethylating agent and progress to AML are eligible at&#xD;
             the time of diagnosis of AML regardless any prior therapy for AML. The World Health&#xD;
             Organization (WHO) classification will be used for AML. Patients with MDS, CMML or AML&#xD;
             who have received no prior therapy are eligible if not candidates to receive or refuse&#xD;
             standard therapy.&#xD;
&#xD;
          2. Patients must have evidence of FLT3 activating mutations.&#xD;
&#xD;
          3. Age &gt;/= 18 years&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;/= 2&#xD;
&#xD;
          5. Adequate liver (bilirubin &lt;/= 2x ULN, alanine aminotransferase (ALT) &lt;/= 2.5x ULN) and&#xD;
             renal (creatinine &lt;/= 2x ULN) function&#xD;
&#xD;
          6. Patients must provide written informed consent.&#xD;
&#xD;
          7. Patients must have been off chemotherapy for 2 weeks prior to entering this study,&#xD;
             unless there is evidence of rapidly progressive disease, and must have recovered from&#xD;
             the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients&#xD;
             with rapidly proliferative disease is allowed before the start of study therapy and&#xD;
             for the first four weeks on therapy.&#xD;
&#xD;
          8. Women of childbearing potential must practice contraception. Women considered not of&#xD;
             childbearing potential include any of the following: no menses for at least 5 years or&#xD;
             menses within 5 years but amenorrheic for at least 2 months and luteinizing hormone&#xD;
             (LH) and follicular stimulating hormone (FSH) values within normal range (according to&#xD;
             definition of postmenopausal for laboratory used) or bilateral oophorectomy or&#xD;
             radiation castration and amenorrheic for at least 3 months. Females of childbearing&#xD;
             potential: Recommendation is for 2 effective contraceptive methods during the study.&#xD;
             Adequate forms of contraception are double barrier methods (condoms with spermicidal&#xD;
             jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or&#xD;
             injectable contraceptives, intrauterine devices, and tubal ligation.&#xD;
&#xD;
          9. **continued from above: Male patients with female partners who are of childbearing&#xD;
             potential: Recommendation is for male and partner to use at least 2 effective&#xD;
             contraceptive methods, as described above, during the study.&#xD;
&#xD;
         10. Sexually active males should use a condom during intercourse while taking drug and for&#xD;
             3 months after stopping midostaurin medication. They should not father a child in this&#xD;
             period. A condom is required to be used also by vasectomized men in order to prevent&#xD;
             delivery of the drug via seminal fluid .&#xD;
&#xD;
         11. Negative urine or serum pregnancy test within 2 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known allergy or hypersensitivity to PKC412, mannitol or 5-azacytidine,&#xD;
             or any of their components.&#xD;
&#xD;
          2. Patients who have received any treatment of midostaurin prior to study entry.&#xD;
&#xD;
          3. Patients with known impairment of gastrointestinal (GI) function or GI disease that&#xD;
             may significantly alter the absorption of PKC412.&#xD;
&#xD;
          4. Patients who demonstrated primary resistance to any FLT3 inhibitor or who relapsed&#xD;
             while on therapy with a FLT3 inhibitor.&#xD;
&#xD;
          5. Patients with any other known disease (except carcinoma in-situ) concurrent severe&#xD;
             and/or uncontrolled medical condition (e.g. uncontrolled diabetes with fasting glucose&#xD;
             &gt; 200 mg/dl despite optimal management, cardiovascular disease including congestive&#xD;
             heart failure (NYHA Class III or IV), myocardial infarction within 6 months and poorly&#xD;
             controlled hypertension with systolic &gt; 160 mmHg and diastolic &gt; 100 mmHg, chronic&#xD;
             renal disease, or active uncontrolled systemic infection) which could compromise&#xD;
             participation in the study.&#xD;
&#xD;
          6. Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.&#xD;
             HIV patients not on specific antiretroviral therapy are eligible for participation.&#xD;
&#xD;
          7. Patients who have had any major surgical procedure within 14 days of Day 1.&#xD;
&#xD;
          8. Patients unwilling or unable to comply with the protocol.&#xD;
&#xD;
          9. Patients with known advanced malignant disease of the central nervous system.&#xD;
&#xD;
         10. Impaired cardiac function including any of the following: Screening ECG with a&#xD;
             corrected QT interval (QTc) &gt; 470 msec; Patients with congenital long QT syndrome;&#xD;
             History or presence of sustained ventricular tachycardia; Any history of ventricular&#xD;
             fibrillation or torsades de pointes; Bradycardia defined as Heart Rate (HR) &lt; 50 bpm;&#xD;
             Right bundle branch block + left anterior hemiblock (bifascicular block); Patients&#xD;
             with myocardial infarction or unstable angina &lt; 6 months prior to starting study drug;&#xD;
             congestive heart failure (CHF) NY Heart Association class III or IV; Patients with an&#xD;
             ejection fraction &lt; 50% assessed by multigated radionuclide angiography (MUGA) or&#xD;
             echocardiogram (ECHO) scan within 14 days of Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2016</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Refractory acute leukemias</keyword>
  <keyword>Relapsed acute leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>5-Azacytidine</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>5-aza</keyword>
  <keyword>Vidaza</keyword>
  <keyword>5-AZC</keyword>
  <keyword>AZA-CR</keyword>
  <keyword>Ladakamycin</keyword>
  <keyword>NSC-102816</keyword>
  <keyword>PKC412</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: March 2, 2011 to October 01, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>There were 57 participants for enrollment, one participant was a screen failure and two withdrew consent without receiving the study drug treatment and are therefore excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>5-azacytidine 75 mg/m2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="P2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>5-azacytidine 75 mg/m2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="P3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>5-azacytidine (AZA) 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="B2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="B3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="40" upper_limit="68"/>
                    <measurement group_id="B2" value="62" lower_limit="38" upper_limit="85"/>
                    <measurement group_id="B3" value="67" lower_limit="21" upper_limit="83"/>
                    <measurement group_id="B4" value="65" lower_limit="21" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
        <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
            <description>AZA 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
            <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O3">
            <title>Phase II: 5-azacytidine + PKC412</title>
            <description>AZA 75 mg/m^2 on days 1-7 and PKC412 Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1</title>
          <description>Criteria for response per international working group for Myelodysplastic Syndrome (MDS) &amp; acute myeloid leukemia (AML) where responders obtained a complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%. Clinical responses evaluated using RECIST version 1.1 criteria after every two cycles, with confirmation of clinical response at 4 weeks after achieving response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete w/Incomplete Bone Marrow Recovery (CRi)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphologic Leukemia-Free Status (MLFS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response (OR) Within 6 Months</title>
        <description>Overall response defined as number of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation. complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
            <description>AZA 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
            <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
          </group>
          <group group_id="O3">
            <title>Phase II: 5-azacytidine + PKC412</title>
            <description>AZA 75 mg/m^2 on days 1-7 and PKC412 Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (OR) Within 6 Months</title>
          <description>Overall response defined as number of participants with response as follows: (OR = CR [complete response (CR) rate] + CRi [complete remission with incomplete count recovery] + PR [partial remission] + HI [hematologic improvement]) within 6 months of treatment initiation. complete remission (CR), a CR with incomplete bone marrow recovery (CRi), a morphologic leukemia-free status (MLFS), or a partial remission (PR). CR: &lt;5% bone marrow blasts, neutrophil count&gt;1.0 X10⁹/L, &amp; platelet count&gt;100 X10⁹/L. CRi: all CR criteria except residual neutropenia (&lt;1.0 X10⁹/L) or thrombocytopenia (&lt;100 X10⁹/L). MLFS: &lt;5% blasts in bone marrow regardless of neutrophil &amp; platelet count in peripheral blood. PR: all CR criteria, except reduction&gt; 50% in bone marrow blasts, but still &gt;5%.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from the time of the first protocol-specific intervention with each 21 day cycle until 30 days after the last dose of drug, about 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I: 5-azacytidine + PKC412 25 mg</title>
          <description>AZA 75 mg/m^2/day subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 25 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="E2">
          <title>Phase I: 5-azacytidine + PKC412 50 mg</title>
          <description>AZA 75 mg/m^2/day SQ or IV on days 1-7 of a 28 day cycle. PKC412 50 mg orally twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).</description>
        </group>
        <group group_id="E3">
          <title>Phase II: 5-azacytidine + PKC412</title>
          <description>AZA 75 mg/m^2 on days 1-7 and PKC412 Midostaurin 50 mg bid orally on day 8-21 during the first cycle and continuously thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenia Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection of blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Left Ventricular systolic dysfuction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain (General)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Progressive Disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain, Bone/Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complication Surgical medical procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection from catheter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Abnormal Absolute Neutrophile Count</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QTc prolongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelet Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="40" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Prolongation of QT interval</sub_title>
                <description>Electrocardiogram QT corrected interval prolonged</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abnormal liver function test (LFT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, MD/Professor, Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>1-877-632-6789</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

